Description: Imara, Inc. engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. Its product candidate, IMR-687 is a highly selective and small molecule inhibitor of PDE9. The company was founded by James G. McArthur in 2016 and is headquartered in Cambridge, MA.
Home Page: imaratx.com
IMRA Technical Analysis
116 Huntington Avenue
Boston,
MA
02116
United States
Phone:
617 206 2020
Officers
| Name | Title |
|---|---|
| Dr. Rahul D. Ballal Ph.D. | Pres, CEO & Director |
| Mr. Michael P. Gray MBA, CPA | CFO & COO |
| Mr. Stephen M. Migausky J.D. | Sr. VP of Legal & Gen. Counsel |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.9686 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2020-03-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 41 |